Lilly's Mounjaro could be market leading therapy for T2D and obesity, says analyst

27 June 2022

With strong results from its SURPASS program for gastric inhibitory peptide/glucagon-like peptide-1 receptor (GIP/GLP-1) dual agonist Mounjaro (tirzepatide) for the treatment of type 2 diabetes (T2D), US pharma major Eli Lilly’s (NYSE: LLY) can expect Mounjaro to gain a significant share of the GLP-1 and wider T2D and obesity markets.

Moreover, according to data and analytics company GlobalData, Mounjaro will also threaten Danish diabetes care giant Novo Nordisk’s (NOV: N) Ozempic (semaglutide), which has a dominant share of the GLP-1 market.

Mounjaro is a once-weekly, subcutaneously administered therapy that presents significant promise for patients with both T2D and obesity. Additionally, trials are underway for the use of Mounjaro for heart failure (HF) patients, which will potentially widen its use to patients with T2D, obesity and cardiorenal disease. The drug was approved by the US Food and Drug Administration last month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK